Super-Enhancer–FOXA1–SLC7A11 Axis Drives Disulfidptosis in P
2026-05-14
Super-Enhancer–FOXA1–SLC7A11 Axis Drives Disulfidptosis in Prostate Cancer
Study Background and Research Question
Prostate cancer (PCa) is a leading cause of cancer morbidity and mortality among men globally, with a particularly high incidence in Western populations and a rising trend in Asia due to demographic changes (Kang et al., 2025). While early-stage PCa often responds to androgen deprivation therapy (ADT), advanced disease frequently transitions to castration-resistant prostate cancer (CRPC), which is resistant to conventional therapies and displays a poor response to immune checkpoint inhibitors. Programmed cell death mechanisms—including ferroptosis, autophagy, and necroptosis—have shown therapeutic potential in various cancers. Recently, a novel subtype known as disulfidptosis, characterized by cytoskeletal collapse under glucose starvation and high SLC7A11 activity, has been proposed as an additional therapeutic avenue. The present study by Kang et al. focuses on unraveling the regulatory mechanisms underlying disulfidptosis in PCa, with a particular emphasis on super-enhancer (SE)-mediated transcriptional control.Key Innovation from the Reference Study
The central innovation of this research lies in delineating a super-enhancer–FOXA1–SLC7A11 regulatory axis that orchestrates disulfidptosis in prostate cancer cells. Using integrated bioinformatics, genetic, and molecular biology approaches, the study demonstrates that a specific super-enhancer (located at chr14:37583488–37589585) drives FOXA1 expression, which in turn transcriptionally activates SLC7A11. Notably, SLC7A11 was shown to mediate both pro-tumorigenic phenotypes—promoting proliferation, migration, and invasion—and the induction of disulfidptosis under glucose-deprived conditions (Kang et al., 2025). This work is significant because it connects the emerging field of super-enhancer biology with a newly recognized form of cell death, offering mechanistic insight into how the tumor microenvironment and epigenetic regulation converge to influence prostate cancer viability and progression.Methods and Experimental Design Insights
Kang et al. employed a multi-tiered approach to dissect the SE/FOXA1/SLC7A11 axis:- Bioinformatics and Machine Learning: The authors integrated The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets to identify disulfidptosis-related genes in prostate cancer. Machine learning algorithms were used to prioritize candidate regulators.
- Cell Line Modeling: SLC7A11-overexpressing and knockout prostate cancer cell lines were generated to probe the gene's functional effects.
- Functional Assays: Cell proliferation, migration, and invasion were assayed under both normal and glucose-starved conditions. Disulfidptosis was pharmacologically induced using BAY-876, a glucose uptake inhibitor, to validate the cell death phenotype.
- Chromatin Profiling: CUT&Tag and ChIP-seq assays mapped the FOXA1 binding landscape and super-enhancer regions. Luciferase reporter assays confirmed transcriptional regulation.
- CRISPR-Cas9 Editing: Deletion of the super-enhancer region was performed to assess its necessity for FOXA1 and SLC7A11 expression and for the induction of disulfidptosis.
Protocol Parameters
- apoptosis assay | Annexin V/PI; 24–48 h post-treatment | SLC7A11-modified PCa cells | Quantifies cell death due to disulfidptosis or related pathways | paper
- cell cycle arrest assay | PI staining; 24 h | SLC7A11 overexpression and knockout models | Detects G1/S phase alterations linked to super-enhancer activity | paper
- CRISPR-Cas9 editing | sgRNA targeting chr14:37583488–37589585 | SE/FOXA1/SLC7A11 axis dissection | Deletion efficiency and transcriptional impact | paper
- BAY-876 induction | 2–5 μM; 24–48 h | Pharmacologic disulfidptosis induction | Mimics metabolic stress in vitro | paper
- ChIP-seq/CUT&Tag | FOXA1 antibody, validated conditions | Mapping enhancer–promoter interactions | Identifies regulatory regions for SLC7A11 | paper
- BET inhibitor use | 0.25–1 μM; 24–72 h | Modulation of enhancer-driven transcription | Workflow recommendation for super-enhancer studies | workflow_recommendation
Core Findings and Why They Matter
The study’s principal findings are as follows:- Identification of a Disulfidptosis Gene Signature: SLC7A11 emerged as a central mediator of disulfidptosis in PCa, with high expression correlating with increased cell proliferation and invasiveness. Under glucose-limiting conditions, SLC7A11 overexpression triggered disulfidptosis, a phenotype that could be recapitulated with BAY-876.
- Super-Enhancer–FOXA1 Regulation: Chromatin mapping revealed that FOXA1 is transcriptionally driven by a super-enhancer; loss of this enhancer via CRISPR-Cas9 diminished both FOXA1 and SLC7A11, reducing disulfidptosis susceptibility.
- Therapeutic Implication: The SE/FOXA1/SLC7A11 axis represents a critical vulnerability in PCa, particularly in glucose-starved tumor microenvironments. Targeting this pathway could enable selective induction of cell death or modulation of tumor growth in otherwise therapy-resistant settings (Kang et al., 2025).
Comparison with Existing Internal Articles
Recent internal reviews have explored the role of BET bromodomain inhibitors, such as I-BET151 (GSK1210151A), in regulating super-enhancer activity and associated transcriptional programs in cancer biology (internal analysis). These reviews highlight I-BET151’s ability to disrupt the interaction between BET proteins (BRD2, BRD3, BRD4) and acetylated chromatin, resulting in the downregulation of key oncogenic drivers and the induction of cell cycle arrest and apoptosis (internal resource). Importantly, translational articles have begun to contextualize BET inhibitors as tools to interrogate not only canonical transcriptional programs but also newer cell death modalities, including disulfidptosis (internal review). The reference study advances this field by characterizing a specific super-enhancer–controlled pathway (FOXA1/SLC7A11) that could be functionally interrogated using selective BET inhibitors—thus offering a bridge between mechanistic discovery and translational research applications.Limitations and Transferability
While the findings are robust and provide mechanistic clarity in cell line models, several limitations merit attention:- Cell Line Dependency: Most experiments were conducted in established prostate cancer cell lines, which may not fully capture the diversity of tumor microenvironments or genetic backgrounds found in patients.
- Glucose Starvation Model: Disulfidptosis was primarily assessed under glucose-deprived conditions, which, while relevant to solid tumor physiology, may not reflect all in vivo settings.
- CRISPR-Cas9 Off-Target Effects: Although targeted deletion of the super-enhancer was effective, potential off-target effects or compensatory mechanisms were not exhaustively explored.
- Therapeutic Target Validation: The translational potential of directly targeting the SE/FOXA1/SLC7A11 axis will require further validation in animal models and clinical samples.